Clinical decision making and the expected value of information

Background The results of the HOPE study, a randomized clinical trial, provide strong evidence that 1) ramipril prevents the composite outcome of cardiovascular death, myocardial infarction or stroke in patients who are at high risk of a cardiovascular event and 2) ramipril is cost-effective at a threshold willingness-to-pay of $10 000 to prevent an event of the composite outcome. In this report the concept of the expected value of information is used to determine if the information provided by the HOPE study is sufficient for decision making in the US and Canada. Methods and results Using the cost-effectiveness data from a clinical trial, or from a meta-analysis of several trials, one can determine, based on the number of future patients that would benefit from the health technology under investigation, the expected value of sample information (EVSI) of a future trial as a function of proposed sample size. If the EVSI exceeds the cost for any particular sample size then the current information is insufficient for decision making and a future trial is indicated. If, on the other hand, there is no sample size for which the EVSI exceeds the cost, then there is sufficient information for decision making and no future trial is required. Using the data from the HOPE study these concepts are applied for various assumptions regarding the fixed and variable cost of a future trial and the number of patients who would benefit from ramipril. Conclusions Expected value of information methods provide a decision-analytic alternative to the standard likelihood methods for assessing the evidence provided by cost-effectiveness data from randomized clinical trials. Clinical Trials 2007; 4: 279—285. http://ctj.sagepub.com

[1]  M. J. R. Healy,et al.  Economic Choice of the Amount of Experimentation , 1956 .

[2]  Hamid. Pezeshk,et al.  How large should a clinical trial be , 2000 .

[3]  J Halpern,et al.  Designing a cost-effective clinical trial. , 1995, Statistics in Medicine.

[4]  S. Yusuf,et al.  Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study , 2003 .

[5]  C. J. Adcock,et al.  The choice of sample size. Commentaries. Author's reply , 1997 .

[6]  J Hornberger,et al.  The cost-benefit of a randomized trial to a health care organization. , 1998, Controlled clinical trials.

[7]  K Claxton,et al.  An economic approach to clinical trial design and research priority-setting. , 1996, Health economics.

[8]  Andrew R Willan,et al.  Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial , 2000, The Lancet.

[9]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[10]  D. Lindley.  The choice of sample size , 1997 .

[11]  B W Brown,et al.  The sample size for a clinical trial: A Bayesian–decision theoretic approach , 2001, Statistics in medicine.

[12]  John Gittins,et al.  Quantitative Methods in the Planning of Pharmaceutical Research , 1996 .

[13]  K M Thompson,et al.  A dynamic programming approach to the efficient design of clinical trials. , 2001, Journal of health economics.

[14]  John Gittins,et al.  A Behavioral Bayes Method for Determining the Size of a Clinical Trial , 2000 .

[15]  Howard Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .

[16]  Hamid Pezeshk,et al.  A Fully Bayesian Approach to Calculating Sample Sizes for Clinical Trials with Binary Responses , 2002 .

[17]  A R Willan,et al.  Argon green vs. krypton red laser photocoagulation for extrafoveal choroidal neovascularization secondary to age-related macular degeneration: 3-year results of a multicentre randomized trial. Canadian Ophthalmology Study Group. , 1996, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[18]  Andrew R Willan,et al.  The value of information and optimal clinical trial design , 2005, Statistics in medicine.

[19]  A O'Hagan,et al.  Bayesian Assessment of Sample Size for Clinical Trials of Cost-Effectiveness , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[20]  H. Raiffa,et al.  Applied Statistical Decision Theory. , 1961 .

[21]  Hamid Pezeshk,et al.  Bayesian techniques for sample size determination in clinical trials: a short review , 2003, Statistical methods in medical research.